BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12040668)

  • 1. [Genetic polymorphisms of drug metabolizing enzymes].
    Fujieda M; Yamazaki H; Kamataki T
    Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase.
    Anderson GD
    J Gend Specif Med; 2002; 5(1):25-33. PubMed ID: 11859684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
    Yokoi T; Kamataki T
    Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic polymorphism of drug metabolizing enzymes].
    Yokoi T; Kamataki T
    Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
    [No Abstract]   [Full Text] [Related]  

  • 5. Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms.
    Tabrizi AR; McGrath SD; Blinder MA; Buchman TG; Zehnbauer BA; Freeman BD
    Am J Hematol; 2001 Jun; 67(2):144-6. PubMed ID: 11343389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic differences in drug disposition.
    May DG
    J Clin Pharmacol; 1994 Sep; 34(9):881-97. PubMed ID: 7983231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Individualization of drug therapy and pharmacogenetics].
    Yamamoto I; Azuma J
    Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J; Thum T
    Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
    Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Status of pharmacogenomics and its future role in drug therapy].
    Cascorbi I
    Internist (Berl); 2002 Apr; 43(4):506-10. PubMed ID: 12053407
    [No Abstract]   [Full Text] [Related]  

  • 11. [Genetic polymorphism of the CYP2C subfamily].
    Chiba K
    Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
    Miners J
    Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
    [No Abstract]   [Full Text] [Related]  

  • 13. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese].
    Yokoi T; Kamataki T
    Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):5-14. PubMed ID: 9755457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphism of cytochrome P450 and methods for its determination.
    Buzková H; Pechandová K; Slanar O; Perlík F
    Prague Med Rep; 2006; 107(4):383-93. PubMed ID: 17402551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
    Minoletti C; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mimicking gene defects to treat drug dependence.
    Sellers EM; Tyndale RF
    Ann N Y Acad Sci; 2000; 909():233-46. PubMed ID: 10911933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of CYP2C subfamily in a Japanese population.
    Ieiri I; Higuchi S
    J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448
    [No Abstract]   [Full Text] [Related]  

  • 18. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure.
    Lewis DF
    Xenobiotica; 2002 Apr; 32(4):305-23. PubMed ID: 12028664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
    Thijssen HH; Verkooijen IW; Frank HL
    Pharmacogenetics; 2000 Nov; 10(8):757-60. PubMed ID: 11186138
    [No Abstract]   [Full Text] [Related]  

  • 20. Georges Brohee Prize 1996. Major cytochrome P-450 families: implications in health and liver diseases.
    Horsmans Y
    Acta Gastroenterol Belg; 1997; 60(1):2-10. PubMed ID: 9144971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.